Evaluation of the efficacy of potassium iodide preparation for radioactive iodine therapy in Graves' disease

Evaluation of the efficacy of potassium iodide preparation for radioactive iodine therapy in Graves' disease - Evaluation of the efficacy of potassium iodide preparation for radioactive iodine therapy in Graves' disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024893

Enrollment

Registered

2016-12-01

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria was defined as follows; more than 18 years old at RAIT.

Exclusion criteria

Exclusion criteria: The exclusion criteria was defined as follows; large goiter and/or experience of previous RAIT. The definition of large goiter in exclusion criteria was determined that estimated thyroid gland weight was more than 50 g.

Design outcomes

Primary

Measure	Time frame
variation of FT4 between before and at 4 days after discontinuation of methimazole (MMI) or KI between KI prepariton group and MMI preparation group	—

Secondary

Measure	Time frame
Radioactive iodine uptake before RAIT, thyroid gland weight, dose of administered 131-I, dose of 131-I based on thyroid gland weight, free thyroxine (FT4) at RAIT, thyroid function at one year after RAIT and thyroid gland weight at one year after RAIT between above two gruops	—

Countries

Japan

Contacts

Public ContactSeigo Tachibana

Yamashita thyroid and parathyroid clinic Endocrinology

sei.tac.thyroid@gmail.com092-281-1300

Outcome results